Overview

A Rollover Protocol of Elacestrant, in Combination With Onapristone, for Patients With ER+, PR+, HER2- Advanced or Metastatic Breast Cancer

Status:
WITHDRAWN

Trial end date:
2023-12-01

Target enrollment:

Participant gender:

Summary

This is a rollover study for patients enrolled in the discontinued ELONA clinical trial (ONA-XR-103) with the primary objective to characterize the safety of elacestrant in combination with onapristone either alone or in combination.

Phase:

PHASE1

Details

Lead Sponsor:

Context Therapeutics Inc.

Treatments:

elacestrant
onapristone
RAD1901